Skip to main content
Premium Trial:

Request an Annual Quote

Takara Bio, BioSyntagma Develop High-Throughput SARS-CoV-2 Detection Method

NEW YORK – Takara Bio USA announced Monday it has collaborated with BioSyntagma and their partners to develop and validate a high-throughput SARS-CoV-2 detection method.

The method uses Takara Bio's SmartChip PCR instrument, chips, and reagents to run 5,184 reactions per chip in less than 30 minutes of direct hands-on time, the company said in a statement. Each chip can run 384 samples or assays and supports 14 different sample and assay configurations. Because each reaction is at nanoliter scale, the standard preamplification step is eliminated and variability is reduced. There are also less reagents used, reducing costs, the Mountain View, California-based subsidiary of Japanese firm Takara Bio added.

BioSyntagma, a biotech spinoff of Arizona State University based in Scottsdale, Arizona, is the development and validation partner of P2 Diagnostics and will adopt the SmartChip testing method. BioSyntagma is seeking Emergency Use Authorization from the US Food and Drug Administration for SARS-CoV-2 detection using the SmartChip method. Ipsum Diagnostics and Hackensack University Medical Center received EUA for their SARS-CoV-2 tests that use Takara Bio's RT-PCR reagents, the company said.  

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more